OBJECTIVE: Although low bone mineral density (BMD) is prevalent in HIV, changes in BMD over time remain unclear. We aimed to compare rates of, and factors associated with, BMD change between HIV-positive and HIV-negative subjects. METHODS: In a prospective, 3-year cohort, HIV-positive and HIV-negative subjects provided annual demographic and clinical data, fasting bloods and dual x-ray absorptiometry (DXA). Using longitudinal mixed models we compared and determined predictors of rate of change in BMD. RESULTS: Of 384 subjects (45.8% HIV-positive), 120 contributed two and 264 contributed three BMD measurements. Those with HIV were younger (median (IQR) 39 (34-46) vs 43 (35-50) years; p=0.04), more often male (61% vs 46%; p = 0.003) and less likely Caucasian (61% vs 82%; p 30 years, Caucasian ethnicity, and not being on ART during follow-up were associated with greater decline and higher parathyroid hormone associated with a smaller decline in BMD at the femoral neck. We found no association between BMD change and exposure to tenofovir disoproxil fumarate or protease inhibitors. CONCLUSIONS: We observed no difference in rate of BMD decline regardless of HIV status and in HIV positive subject, having started ART within the previous three months was the only factor associated with greater BMD decline at all 3 sites
